Get the Stockscreener App
51.87
0.51%
-0.28
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $51.87, with a volume of 4.72M.
It is down -0.51% in the last 24 hours and up +11.13% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$52.15
Open:
$52.2
24h Volume:
4.72M
Relative Volume:
0.30
Market Cap:
$105.60B
Revenue:
$48.03B
Net Income/Loss:
$6.05B
P/E Ratio:
17.51
EPS:
2.9615
Net Cash Flow:
$15.30B
1W Performance:
+5.50%
1M Performance:
+11.13%
6M Performance:
+7.18%
1Y Performance:
-12.62%
1-Day Range:
$51.82
$52.41
1-Week Range:
$48.22
$52.51
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
51.88 | 106.16B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
993.54 | 904.25B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.50 | 486.51B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.24 | 399.57B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.58 | 253.59B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.06 | 247.51B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb a Top 25 Dividend Giant With 4.76% Yield (BMY) - Nasdaq
Bristol-Myers Squibb Stock Gains Momentum from Key Regulatory Approval - AD HOC NEWS
14 Best US Stocks to Buy for Long Term - Insider Monkey
Antibody Discovery Market to Reach USD 17.68 Billion by 2032, Driven by Rising Demand for Targeted Therapies and Advancements in AI Powered Antibody Engineering – SNS Insider - GlobeNewswire Inc.
Cresset Asset Management LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Epoch Investment Partners Inc. - MarketBeat
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable” - Insider Monkey
Do These 3 Healthcare Stocks Need a Checkup? - Finviz
What's Going On With Bristol-Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his ‘patent cliff’ plan - Fortune
First Trust Advisors LP Has $212.59 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) – Company AnnouncementFT.com - Financial Times
DEERFIELD MANAGEMENT COMPANY, L.P.'s Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
Water stewardship for environmental sustainability - Bristol Myers Squibb
How risky is Bristol Myers Squibb Company stock compared to peers2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - Newser
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities - Sahm
BMY Gains on News of Continuation of Alzheimer's Disease Study - Finviz
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Scotiabank raises Bristol-Myers Squibb stock price target to $53 on pipeline - Investing.com Nigeria
Invesco Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CW Advisors LLC Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Why Bristol Myers Squibb Company Celegne Contingent stock is a must watch tickerGlobal Markets & Stock Timing and Entry Methods - Newser
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025 - ts2.tech
What's Going On With Bristol-Myers Squibb Shares Wednesday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Shares of Bristol Myers Squibb rise despite delay in clinical trial of promising drug - MarketWatch
Bristol-Myers Squibb stock holds Buy rating at Truist despite trial delay - Investing.com
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why. - MarketWatch
After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis - BioPharma Dive
Bristol Myers Squibb (BMY) Delays Alzheimer's Drug Trial Results - GuruFocus
Bristol Myers (BMY) Extends ADEPT-2 Study Timeline for Key Alzhe - GuruFocus
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
Bristol Myers (BMY) Bolsters ADEPT-2 Alzheimer's Study with More Participants - GuruFocus
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb - Yahoo Finance
Bristol Myers Stock Jumps As Wall Street Backs Added Enrollment In Alzheimer’s Trial — Retail Calls It ‘Worth A Play’ - Stocktwits
Drug Trial Wins Give Health Care Stocks A Shot - Finimize
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Bristol Myers rises as Alzheimer's trial to enroll more patients - TradingView
M&T Bank Corp Sells 23,588 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Expands ADEPT-2 Study to Address Irregularit - GuruFocus
River Road Asset Management LLC Sells 67,650 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
BMS to enroll more patients in Alzheimer’s psychosis drug trial - Investing.com
Bristol Myers Squibb stock rises after continuing Phase 3 Alzheimer’s study - Investing.com Canada
Loomis Sayles & Co. L P Boosts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease - Yahoo Finance
Independent Franchise Partners LLP Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Stock Rises on Alzheimer’s Drug Study Update - The Wall Street Journal
Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates - Insider Monkey
BMS Executive: AI to Reshape Pharmaceutical, Biotech Industries - 조선일보
Bristol-Myers Squibb (BMY): Assessing Value After a Recent Short-Term Share Price Rebound - simplywall.st
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):